» Articles » PMID: 38644492

An Exosomal Strategy for Targeting Cancer-associated Fibroblasts Mediated Tumors Desmoplastic Microenvironments

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2024 Apr 21
PMID 38644492
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors desmoplastic microenvironments are characterized by abundant stromal cells and extracellular matrix (ECM) deposition. Cancer-associated fibroblasts (CAFs), as the most abundant of all stromal cells, play significant role in mediating microenvironments, which not only remodel ECM to establish unique pathological barriers to hinder drug delivery in desmoplastic tumors, but also talk with immune cells and cancer cells to promote immunosuppression and cancer stem cells-mediated drug resistance. Thus, CAFs mediated desmoplastic microenvironments will be emerging as promising strategy to treat desmoplastic tumors. However, due to the complexity of microenvironments and the heterogeneity of CAFs in such tumors, an effective deliver system should be fully considered when designing the strategy of targeting CAFs mediated microenvironments. Engineered exosomes own powerful intercellular communication, cargoes delivery, penetration and targeted property of desired sites, which endow them with powerful theranostic potential in desmoplastic tumors. Here, we illustrate the significance of CAFs in tumors desmoplastic microenvironments and the theranostic potential of engineered exosomes targeting CAFs mediated desmoplastic microenvironments in next generation personalized nano-drugs development.

Citing Articles

Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment.

Xie J, Lin X, Deng X, Tang H, Zou Y, Chen W Cancer Drug Resist. 2025; 8:2.

PMID: 39935427 PMC: 11810458. DOI: 10.20517/cdr.2024.152.


Drug Delivery System Targeting Cancer-Associated Fibroblast for Improving Immunotherapy.

Zhang Z, Wang R, Chen L Int J Nanomedicine. 2025; 20():483-503.

PMID: 39816375 PMC: 11734509. DOI: 10.2147/IJN.S500591.


Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications.

Biray Avci C, Bagca B, Nikanfar M, Takanlou L, Takanlou M, Nourazarian A Front Pharmacol. 2024; 15:1442888.

PMID: 39600368 PMC: 11588459. DOI: 10.3389/fphar.2024.1442888.

References
1.
Stuelten C, Dacosta Byfield S, Arany P, Karpova T, Stetler-Stevenson W, Roberts A . Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci. 2005; 118(Pt 10):2143-53. DOI: 10.1242/jcs.02334. View

2.
Arina A, Idel C, Hyjek E, Alegre M, Wang Y, Bindokas V . Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A. 2016; 113(27):7551-6. PMC: 4941507. DOI: 10.1073/pnas.1600363113. View

3.
Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z . Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021; 135:567-581. DOI: 10.1016/j.actbio.2021.09.003. View

4.
Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S . CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012; 72(11):2768-79. PMC: 3367125. DOI: 10.1158/0008-5472.CAN-11-3567. View

5.
Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang J . Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Mol Ther. 2019; 28(2):536-547. PMC: 7001084. DOI: 10.1016/j.ymthe.2019.11.020. View